Vivos Therapeutics (VVOS) Cost of Revenue (2020 - 2026)
Vivos Therapeutics (VVOS) reported Cost of Revenue of $249000.0 for Q1 2026, down 30.45% year-over-year from $358000.0 in Q1 2025, and down 34.82% on a QoQ basis from $382000.0 in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Cost of Revenue data on file, last reported at $249000.0 in Q1 2026.
- Quarterly Cost of Revenue fell 30.45% year-over-year to $249000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 80.97% YoY) and the FY2025 annual result came in at $1.4 million, down 76.71% from the prior year.
- Cost of Revenue fell to $249000.0 in Q1 2026 per VVOS's latest filing, from $382000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.7 million in Q4 2024 and bottomed at -$1.9 million in Q4 2023.
- The 5-year median for Cost of Revenue is $641000.0 (2023), against an average of $966352.9.
- The widest annual swing landed in 2023, when Cost of Revenue slumped 221.58%; it then soared 346.48% in 2024.
- Tracing VVOS's Cost of Revenue over 5 years: stood at $1.6 million in 2022, then tumbled by 221.58% to -$1.9 million in 2023, then soared by 346.48% to $4.7 million in 2024, then slumped by 91.86% to $382000.0 in 2025, then sank by 34.82% to $249000.0 in 2026.
- Per Business Quant, the three latest VVOS Cost of Revenue figures stand at $249000.0 (Q1 2026), $382000.0 (Q4 2025), and $403000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.89 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 2.21 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 3.26 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.59 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 362.60 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.51 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 441.60 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 481.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 891.20 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 249,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 249,000.00 |
| Mar 31, 2026 | 249,000.00 |
| Dec 31, 2025 | 5.88 Mn |
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 403,000.00 |
| Sep 30, 2025 | 403,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 320,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Mar 31, 2024 | 1.48 Mn |
| Mar 31, 2024 | 1.48 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.30 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 901,000.00 |
| Dec 31, 2022 | 901,000.00 |
| Sep 30, 2022 | 1.75 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 753,000.00 |
| Mar 31, 2022 | 753,000.00 |
| Dec 31, 2021 | 2.56 Mn |
| Dec 31, 2021 | 2.56 Mn |
| Sep 30, 2021 | 1.36 Mn |
| Sep 30, 2021 | 1.36 Mn |
| Jun 30, 2021 | 873,000.00 |
| Jun 30, 2021 | 873,000.00 |
| Mar 31, 2021 | 860,000.00 |
| Mar 31, 2021 | 860,000.00 |
| Dec 31, 2020 | 1.16 Mn |
| Dec 31, 2020 | 1.16 Mn |
| Sep 30, 2020 | 431,704.00 |
| Sep 30, 2020 | 431,704.00 |
| Jun 30, 2020 | 544,846.00 |
| Jun 30, 2020 | 544,846.00 |
| Mar 31, 2020 | 780,456.00 |
| Mar 31, 2020 | 780,456.00 |